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http://dx.doi.org/10.1016/j.jfma.201May-Hegglin anomaly (MHA) is a rare autosomal dominant disorder characterized by the triad of
thrombocytopenia, giant platelets, and inclusion bodies in leukocytes. Recent evidence links
MHA to mutations in the MYH9 gene. MHA has not been reported in Taiwan before. We report
a 25-year-old Taiwanese man who presented with prolonged bleeding after dental extraction.
Examination of peripheral blood smear revealed thrombocytopenia (plateletZ 35,000/mL),
giant platelets, and Do¨hle-like cytoplasmic inclusions in neutrophils. A strong family history of
thrombocytopenia favored hereditary macrothrombocytopenia over idiopathic thrombocyto-
penic purpura (ITP). Electronmicroscopy revealed a spindle shape and parallel order of filaments
in the inclusions, consistent with the diagnosis of MHA. We performed mutational analysis using
polymerase chain reaction followed by direct sequence of the MYH9 gene for the patient, his
maternal uncle and cousin, and all showed the same heterozygous R1933X mutation in exon
40. MHA should be considered when a young patient has thrombocytopenia, frequently misdiag-
nosed as ITP. Morphological examination of peripheral blood smear, family history tracing and
genetic studies are required to make an accurate diagnosis and avoid unnecessary and even
harmful therapies such as corticosteroids and splenectomy.
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R1933X mutation in MYH9 gene in May-Hegglin anomaly 57IntroductionFigure 1 Pedigree of this patient and some affected family
members. PLT Z platelets.Hereditary macrothrombocytopenias with leukocyte inclu-
sion bodies, MYH9 disorders, are a group of rare autosomal
dominant disorders characterized by thrombocytopenia,
giant platelets, and Do¨hle-like inclusions in granulocytes.
MYH9 disorders, including May-Hegglin anomaly (MHA),
Sebastian syndrome, Fechtner syndrome and Epstein
syndrome, all have largely overlapping phenotypes and
result from mutations in the MYH9 gene on chromosome 22,
which encodes the nonmuscle myosin heavy chain-IIA (
NMMHC-IIA) protein.1 To date, at least 33 mutations of the
MYH9 gene have been identified.2,3
MHA was first described by May, a German physician, in
1909, and was subsequently described by Hegglin, a Swiss
physician, in 1945.4 Thrombocytopenia may occur in 50% of
the patients with this anomaly, but severe bleeding is
unusual.5 Most patients are asymptomatic, discovered
incidentally, and require no specific treatment. MHA is
frequently misdiagnosed as idiopathic thrombocytopenic
purpura (ITP) without careful inspection of blood smears
and a thorough family history. The most serious impacts of
this disease are iatrogenic managements due to misdiag-
nosis. Herein, we report a young man presenting with
prolonged bleeding after dental extraction. To the best of
our knowledge, this is the first case report of MHA caused by
R1933X mutation from Taiwan.
Case report
A 25-year-old man visited our hematology clinic due to
prolonged bleeding after dental extraction. He had expe-
rienced several episodes of prolonged nasal bleeding and
conjunctival hemorrhage since childhood. On physical
examination, there was no ecchymosis, petechia or
palpable hepatosplenomegaly, confirmed by abdominal
ultrasonography. The patient displayed normal hearing
function and no cataracts.
Complete blood counts were normal except for throm-
bocytopenia (platelet Z 35,000/mL). Other laboratory
data, including electrolytes, creatinine, blood urea
nitrogen, liver profiles, von Willebrand factor antigen,
prothrombin time, and activated partial thromboplastin
time, were all within normal limits. Urinalysis was unre-
markable. A flow cytometric study, using dual markers of
CD 62P and PAC-1, revealed normal platelet function. The
activated platelets proportion was 1.36% before ADP
(10 mM, final concentration) stimulation, which rose to
63.6% (normal range Z 57.12  17.59%) after ADP stimu-
lation. Bone marrow examination revealed increased
megakaryocytes without dysplasia. Initially, a provisional
diagnosis of ITP was made, based on clinical and laboratory
findings.
However, further review of the family history disclosed
some relatives, including his mother, one uncle, and one
cousin all have thrombocytopenia as well (Fig. 1). All
affected family members did not have nephritis, deafness
and cataract. Therefore, hereditary thrombocytopenia was
considered. A review of the patient’s peripheral blood
smear revealed a few giant platelets and Do¨hle-like cyto-
plasmic inclusions in neutrophils, appearing as conspicuousbright blue oval to spindle shapes, as illustrated in Fig. 2A.
A bone marrow smear disclosed the same inclusions in
myeloid cells (see Fig. 2B). Electron microscopy revealed
giant platelets of about 32 fL in size with adequate alpha
granules and dense particles (Fig. 3A) and leukocyte
inclusions composed of spindle-shaped and parallel ordered
filaments (Fig. 3B), which are consistent with the diagnosis
of MHA. We performed mutational analysis using a poly-
merase chain reaction by amplification of exons 1, 16, 26,
30, 38 and 40, followed by direct DNA sequencing of the
MYH9 gene in the patient, his maternal uncle and cousin. A
heterozygous thymine to cytosine single-base substitution
at nucleotide 5797 (CGA to TGA) was found in exon 40,
resulting in a recurrent mutation from arginine to terminal
at codon 1933 (R1933X), confirming the diagnosis of MHA.Discussion
We report this case and his family with MHA due to
a heterozygous R1933X mutation in the MYH9 gene in
Taiwan. The patient sought medical attention because of
prolonged bleeding after dental extraction. The morpho-
logical features of peripheral blood smear and a family
history of thrombocytopenia pinpointed a hereditary mac-
rothrombocytopenia. MYH9-related disorder was diagnosed
based on leukocyte inclusions in the peripheral blood
smear. Fechtner and Epstein syndromes were not likely,
due to the absence of Alport manifestations, including
nephritis, deafness, and cataract.6 Electron microscopy
clearly demonstrated features of typical MHA, with spindle-
shaped and parallel ordered filaments in leukocyte inclu-
sions. Mutational analysis showed a heterozygous R1933X
mutation, which has been reported as a causative mutation
for MYH9-related disorder.2
Clinical presentations of MHA, as well as MYH9-related
disorders are, usually, mild bleeding tendency, easy
bruising, epistaxis, menorrhagia in woman, and post-
operative hemorrhage, which depend on the severity of
the thrombocytopenia.7,8 Some patients can remain
asymptomatic.9 MYH9-related disorders are sometimes
Figure 2 (A) Giant platelet (red arrow) and Do¨hle-like cytoplasmic inclusion in neutrophil, appearing as conspicuous bright blue
oval to spindle shapes (black arrow) on peripheral blood smear; (B) Do¨hle-like cytoplasmic inclusion in myeloid cells (black arrow)
on bone marrow smear (2A 1000, 2B 1000; all Wright’s stain).
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asymptomatic individuals. MYH9-related disorders cannot
be distinguished from ITP by clinical symptoms and platelet
count. The patient’s family history and careful examination
of the patient’s peripheral blood smear are very important
for distinguishing two diseases (Table 1).
The diagnosis of MYH9-related disorders has been
conventionally made on morphological examination
revealing a triad of giant platelets, thrombocytopenia, and
inclusions in the cytoplasm of leukocytes on May-Grunwald-
Giemsa or Wright’s stained blood smear, where 2e4 mm oval
or spindle-shaped, sky-blue inclusions are present in the
peripheral cytoplasm. Epstein syndrome does not have
leukocyte inclusions. An audiogram, ophthalmologic
screening and renal function assessment (creatinine clear-
ance and proteinuria) should be evaluated for Alport
manifestations, including nephritis, deafness, and cataract.
Fechtner and Epstein syndromes have Alport manifesta-
tions. The MHA is distinguished from Sebastian syndrome by
ultrastructural differences in their leukocyte inclusion
bodies.6 Ultrastructurally, MHA lacks limiting membraneFigure 3 (A) Giant platelet about 32 fL in size with adequate alp
inclusion consists of ribosomes along parallel microfilaments (red aand contains clusters of ribosomes oriented along the axis
of thin parallel filaments 7e10 nm in diameter. Sebastian
syndrome also contains ribosomes, but lacks parallel fila-
ments depolymerized ribosomes.9
Mutation analysis is helpful for the diagnosis of MYH9
disorders, and a full molecular assessment requires
screening of 40 exons. Genetic testing has been postulated
to help assess the risk of the development of high-tone
hearing loss, cataracts, or renal impairment, although
there is debate about the extent of mutation-phenotype
correlation in MYH9 disorders.2 By the reported clinical
features of MYH9 disorders caused by a heterozygous
R1933X mutation, most patients had hearing impairment
and rare renal impairment.2 However, in this patient and
his family, they all did not have renal and hearing function
impairment.
Some subtypes of hereditary macrothrombocytopenias
are associated with mutations in the MYH9 gene on chro-
mosome 22, which encodes 224KD NMMHC-IIA protein.
NMMHC-IIA protein is expressed in many cells, including
platelets, leukocytes, kidney and cochlea, and is involvedha granules and dense particles on electronic microscopy; (B)
rrow) on electron microscopy (3A 25,000, 3B 20,000).
Table 1 Clinical and laboratory differences between MHA and ITP.
MHA ITP
Family history Yes No
Onset Life-long (young age) Recent
Bleeding tendency Mild Variable
Previous normal platelet count No Yes
Blood smear Giant platelet, inclusions in neutrophils Normal or large platelet
Response to platelet transfusion Good Poor
Treatment Observation and supportive treatment Corticosteroid, intravenous immunoglobulin
G, splenectomy
ITP Z idiopathic thrombocytopenic purpura; MHA Z May-Hegglin anomaly.
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tecture.4 Mutations of NMMHC-IIA may alter the composi-
tion of platelet cytoskeleton and impair cytoskeletal
reorganization, which may subsequently cause abnormal
platelet formation from megakaryocytes, resulting in
thrombocytopenia and giant platelets.10,11 Anomalies of
the podocyte cytoskeleton can damage the glomerular
filtration barrier, leading to hematuria and even renal
failure.12 Mechanisms of hearing impairment and cataracts
are still obscure, and probably related to an abnormal
actin-myosin complex.13
There is no known prevention or treatment for the
nonhematopoietic consequences of these disorders.
Platelet transfusion may be useful for bleeding caused by
trauma or surgery. Preoperative use of desmopression
(DDAVP) can be considered in patients with May-Hegglin
anomaly and other MYH9-related disease with thrombocy-
topenia.5 Splenectomy, a treatment for refractory idio-
pathic thrombocytopenic purpura, is contraindicated in all
hereditary macrothrombocytopenias, including MHA.8,14,15
In conclusion, we describe a male patient with MHA, the
first was discovered in Taiwan with R1933X mutation in
MYH9, who presented with prolonged bleeding after dental
extraction. MHA is easily misdiagnosed as idiopathic
thrombocytopenic purpura, if careful inspection of blood
smear and family history are overlooked. Early recognition
of this inherited thrombocytopenia can avoid unnecessary
diagnostic studies, such as bone marrow aspiration and
biopsy, and even harmful therapies with corticosteroids,
immunosuppressive agents and splenectomy.
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